Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

<
'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... surgery or harsh treatments because science fails to ... of the disease. Researchers at Case Western Reserve ... technology that allows patients to safely choose to ... take drastic measures. , The project is one ... biomedical engineering at Case Western Reserve and director ...
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/22/2013)... conclude that the 20 percent reduction in lung ... chest X-ray (CXR) screening previously reported in the ... centers in the United States. , Philadelphia, PAPhysicians ... about the benefits and risks of LDCT lung ... New England Journal of Medicine of the ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... riparian willow warblers and beaver dams once were bountiful in ... once wolves left this area, elk grew more plentiful, browsing ... beavers, and sparrows have replaced the warblers in what is ... the absence of the wolf, a top predator. That's the ...
... on the rise, there is growing interest in maintaining the ... study released this week in the on-line edition of the ... a crucial role in determining how much carbon these natural ... to provide other crucial ecosystem services such as preventing erosion. ...
... tiny flatworm best known for its extraordinary ability to regenerate ... ability of stem cells to differentiate into specialized cells. The ... protein PIWI, an important regulator of stem cells in organisms ... tissue lost to injury or shed during the body's normal ...
Cached Biology News:Wolves' top-down effect 2Seeing the forest and the trees 2Regenerating worms help elucidate stem cell biology 2Regenerating worms help elucidate stem cell biology 3Regenerating worms help elucidate stem cell biology 4
(Date:5/24/2013)... This market report summarizes the ... carried out in May 2013. The full report ... the responses for each question, its segmentation and ... highlights some interesting differences, particularly between Pharma, Biotech ... were developed to estimate the in house and ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: ... and distributor of nutrients for plants and animals, located ... the Company,s management will host a conference call and ... overview of the Company followed by a question and ...
... more than 40 years, marking second FDA approval ... Japan, Feb. 13 Takeda Pharmaceutical Company Limited ... Inc., announced today that the United States Food ... 40 mg and 80 mg for the chronic ...
... DNA testing technology provided by GeneSeek Inc.LINCOLN, Neb., ... will be used for medical-grade source pigs which ... Minnesota non-profit organization providing pig islet cells for ... a certified Illumina CSPro laboratory and global leader ...
Cached Biology Technology:Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 2Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 3Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 4FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 2FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 3FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout 4Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research 2Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research 3
... System provides a simple, rapid and ... glutathione-S-transferase (GST) fusion proteins. Immobilized glutathione ... to isolate GST-tagged protein directly from ... either a manual (requires use of ...
... Useful for the mechanical harvesting of ... and ensures even contact with the growth ... and 75cm flasks • Individually wrapped • ... Linkage: This CLS number is a new ...
... Assay Kits are ideal for studying ... compounds using fluorescence polarization (FP) The ... glutathione transferase to the ligand binding ... and a proprietary, fluorescently-tagged progesterone ligand, ...
... base (YNB) is a base medium for preparation ... contains ammonium sulfate but does not contain amino ... available. Each pouch contains reagents to prepare ... or 1000 ml of 10X YNB for S. ...
Biology Products: